ICER to assess treatments for lupus nephritis

ICER

10 August 2020 - Report will be subject of New England CEPAC meeting in March 2021; Open Input now being accepted until 26 August 2020.

The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals) and belimumab (Benlysta, GlaxoSmithKline) for the treatment of lupus nephritis. 

Voclosporin is seeking an initial approval for the treatment of lupus nephritis, and belimumab is seeking a label expansion for the treatment of lupus nephritis; both are expecting FDA decisions in early 2021.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder